MARI Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Marinomed Biotech AG

Watchlist Manager

Watchlist

Price: 4 EUR Market Closed

Market Cap: €8m

M	Marinomed Biotech AG VSE:MARI	AT
	Shimano Inc OTC:SHMDF	JP
	Ohmoriya Co Ltd TSE:2917	JP

Profitability Summary

Marinomed Biotech AG's profitability score is 50/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

58%

Sustainable 3Y Average Gross Margin

22%

Gross Margin is Increasing

16% > 58%

Exceptional Operating Margin

112%

Negative 3Y Average Operating Margin

-51%

Operating Margin is Increasing

-48% > 112%

Exceptional Net Margin

44%

Negative 3Y Average Net Margin

-122%

Net Margin is Increasing

-55% > 44%

Negative Free Cash Flow Margin

-21%

Negative 3Y Average Free Cash Flow Margin

-54%

Free Cash Flow Margin is Increasing

-50% > -21%

Negative ROE

-41%

Exceptional 3Y Average ROE

Negative 3Y Average ROIC

-18%

ROIC is Increasing

-45% > 174%

View All

Hide

Collapse

50 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.